Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
14.65B
Market cap14.65B
Price-Earnings ratio
18.38
Price-Earnings ratio18.38
Dividend yield
Dividend yield
Average volume
2.08M
Average volume2.08M
High today
$59.72
High today$59.72
Low today
$58.20
Low today$58.20
Open price
$58.75
Open price$58.75
Volume
2.14M
Volume2.14M
52 Week high
$59.72
52 Week high$59.72
52 Week low
$33.76
52 Week low$33.76

Stock Snapshot

As of today, Exelixis(EXEL) shares are valued at $59.09. The company's market cap stands at 14.65B, with a P/E ratio of 18.38.

On 2026-09-03, Exelixis(EXEL) stock traded between a low of $58.20 and a high of $59.72. Shares are currently priced at $59.09, which is +1.5% above the low and -1.1% below the high.

The Exelixis(EXEL)'s current trading volume is 2.14M, compared to an average daily volume of 2.08M.

During the past year, Exelixis(EXEL) stock moved between $33.76 at its lowest and $59.72 at its peak.

During the past year, Exelixis(EXEL) stock moved between $33.76 at its lowest and $59.72 at its peak.

EXEL News

Investor's Business Daily 1d
Cancer Stock Breaks Out To Highs; Key FDA Action On Watch

Research Cancer Stock Breaks Out To Highs; Key FDA Action On Watch Licensing Even as the recent euphoria surrounding a cancer vaccine breakthrough from Moderna...

Cancer Stock Breaks Out To Highs; Key FDA Action On Watch
Simply Wall St 2d
Exelixis Secures CABOMETYX Patent Win Through 2030

Exelixis (NasdaqGS:EXEL) secured a key patent litigation win preserving market exclusivity for CABOMETYX against MSN Laboratories. The court affirmed the valid...

Exelixis Secures CABOMETYX Patent Win Through 2030
TipRanks 3d
Exelixis Secures Key Patent Victory, Extends Exclusivity

The latest announcement is out from Exelixis ( (EXEL) ). On August 31, 2026, Exelixis announced that the U.S. Court of Appeals for the Federal Circuit upheld a...

Analyst ratings

57%

of 21 ratings
Buy
33.3%
Hold
57.1%
Sell
9.5%

More EXEL News

TipRanks 3d
Exelixis says appeals court affirmed ‘key portion’ of 2024 judgment

Exelixis (EXEL) announced that in the lawsuit Exelixis, Inc. vs. MSN Laboratories Private Limited et al., Civil Action No. 22-00228, the U.S. Court of Appeals f...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.